Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    RAPID EC – RCT Assessing Pregnancy with Intrauterine Devices for Emergency Contraception
Previous Study | Return to List | Next Study

RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02175030
Recruitment Status : Completed
First Posted : June 26, 2014
Results First Posted : June 29, 2022
Last Update Posted : June 29, 2022
Information provided by (Responsible Party):
David Turok, University of Utah

Brief Summary:
This study is a randomized trial of two IUDs for emergency contraception: the copper IUD, the most effective method of emergency contraception vs. the levonorgestrel IUD, the most preferred IUD which has never been tested as an emergency contraceptive. This research has the potential to increase use of highly effective contraception in a high-risk population and lower the persistently elevated rate of U.S. unintended pregnancy.

Condition or disease Intervention/treatment Phase
Contraception Drug: Copper IUD Drug: Levonorgestrel IUD Phase 4

Detailed Description:

Unintended pregnancy has multiple adverse effects on both maternal and child health. The United States continues to have one of the highest rates of unintended pregnancy among developed countries. To combat this problem, we are studying initiation of the highly effective intrauterine device (IUD) for women presenting for emergency contraception (EC). This is an ideal population to initiate highly effective reversible contraception (HERC) as they are at high risk of unintended pregnancy and are acting to reduce that risk. We have recently demonstrated significantly lower pregnancy rates 12 months after presenting for EC among women who selected the copper IUD versus those who selected oral Levonorgestrel (LNG).

Not only is the copper IUD the most effective method of EC, it is considered a top tier anticipatory contraception method and its ability to prevent pregnancy is on par with tubal sterilization (less than 1% in the first year with lower failure rates in subsequent years). However, women selecting intrauterine contraception have shown a strong preference for the LNG IUD. The LNG IUD, is as effective at preventing pregnancy as the Copper IUD, and has some non-contraceptive effects that many women see as benefits such as the reduction or elimination of menstrual bleeding and menstrual related discomfort. Of currently available reversible contraceptives, the LNG IUD has the highest levels of user satisfaction and continuation. However, its effectiveness as an emergency contraceptive remains unknown. A randomized control trial is necessary to assess the safety and efficacy of the LNG IUD as EC. Demonstrating the efficacy, safety, and acceptability of the LNG IUD for EC will improve options for women seeking EC and who desire a highly effective method of contraception.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 711 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: RAPID EC - Randomized Controlled Trial Assessing Pregnancy With Intrauterine Devices for Emergency Contraception
Study Start Date : August 2016
Actual Primary Completion Date : February 2020
Actual Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Copper T380 IUD
Randomized to copper T380 IUD for EC (emergency contraception)
Drug: Copper IUD
Randomization to copper/Paragard IUD for emergency contraception
Other Name: Paragard IUD

Active Comparator: LNG20 IUD
Randomized to LNG20 IUD for EC (emergency contraception)
Drug: Levonorgestrel IUD
Randomization to Levonorgestrel/Mirena IUD for emergency contraception
Other Name: Mirena IUD, LNG20 IUD, Levonorgestrel IUD, Liletta IUD

Primary Outcome Measures :
  1. Percentage of Participants Reporting a Pregnancy [ Time Frame: 1 month after enrollment ]
    Urine pregnancy tests within 30 days after IUD insertion will be performed either at home or in clinic. We will use the total number of pregnancies per ARM and the overall number of participants analyzed per ARM to calculate, for each ARM, the percentage of participants reporting a pregnancy in the first month of use of the IUD.

Secondary Outcome Measures :
  1. Number of Participants With Unintended Pregnancy After Initiating the Levonorgestrel IUD Versus the Copper T380 IUD for EC at One Year. [ Time Frame: 1 year after enrollment ]
    Participants will be followed for pregnancies at regular intervals throughout the year and pregnancies will be recorded.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females between 18-35 years old
  • In need of EC (had unprotected intercourse within 120 hours - 5 days)
  • Desire to prevent pregnancy for 1 year
  • Fluent in English and/or Spanish
  • Have a regular menstrual cycle (21-35 days)
  • Know their last menstrual period (+/-3 days)
  • Be willing to comply with the study requirements
  • Desire to initiate an IUD
  • Negative urine pregnancy test

Exclusion Criteria:

  • Current pregnancy
  • Breastfeeding
  • Intrauterine infection within the past three months
  • Sterilization
  • Already have an IUD or contraception implant (Nexplanon) in place
  • Vaginal bleeding of unknown etiology
  • Known Gonorrhea or Chlamydia infection in the last 30 days (unless successfully treated at least 7 days prior to study entry)
  • Known abnormalities of the uterus that distort the uterine cavity
  • Allergy to copper
  • Use of oral Emergency Contraception in the preceeding 5 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02175030

Layout table for location information
United States, Utah
Planned Parenthood Association of Utah
Logan, Utah, United States, 84321
Planned Parenthood Association of Utah
Ogden, Utah, United States, 84403
Planned Parenthood Association of Utah
Orem, Utah, United States, 84057
Planned Parenthood Association of Utah
Salt Lake City, Utah, United States, 84102
Planned Parenthood Association of Utah
South Jordan, Utah, United States, 84095
Planned Parenthood Association of Utah
West Valley City, Utah, United States, 84119
Sponsors and Collaborators
University of Utah
Layout table for investigator information
Principal Investigator: David Turok, MD University of Utah
  Study Documents (Full-Text)

Documents provided by David Turok, University of Utah:
Informed Consent Form  [PDF] November 26, 2019

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: David Turok, M.D., University of Utah Identifier: NCT02175030    
Other Study ID Numbers: 73554
First Posted: June 26, 2014    Key Record Dates
Results First Posted: June 29, 2022
Last Update Posted: June 29, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by David Turok, University of Utah:
Emergency contraception
Levonorgestrel IUD
Copper IUD
Additional relevant MeSH terms:
Layout table for MeSH terms
Contraceptive Agents, Hormonal
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Trace Elements